The analysis, conducted according to PRISMA 2020 standards, drew its evidence from the major Phase 3 programs that defined the modern incretin era: SURMOUNT, testing tirzepatide; STEP, testing injectable semaglutide; SCALE, testing liraglutide 3.0 mg; and OASIS, testing oral semaglutide. From an initial pool of 878 records, independent reviewers narrowed the field to 19 randomized controlled trials meeting strict criteria, including a minimum duration of 12 weeks and standardized body composition or nutritional laboratory measurements. High-potency therapy was defined as any agent or dose producing at least 10 percent mean total body weight reduction, a threshold met by all tirzepatide doses, injectable semaglutide at 1.0 mg or above, and oral semaglutide 50 mg. Liraglutide 3.0 mg was classified as a moderate-potency comparator but retained because the SCALE program remains the only Phase 3 dataset with longitudinal pancreatic enzyme measurements.

The mechanistic foundation of the findings lies in the sheer magnitude of caloric suppression these drugs produce. Once-daily oral semaglutide 50 mg reduced energy intake by a relative 39.20 percent by week 20, translating to a deficit of roughly 1009 kilojoules, about 241 calories, during a single ad libitum lunch compared with placebo. Across the synthesized trials, metabolic models estimated daily energy deficits reaching 1200 kilocalories from baseline, while tirzepatide 15 mg produced a consistent 348.40 kilocalorie per day reduction. Meta-analysis of continuous intake data confirmed this suppression was statistically robust. Critically, these deficits occurred alongside shifts in food preference: participants on tirzepatide showed significant decreases in 10 of 12 food preference categories, blunting desire for high-fat and high-sugar items. The hedonic blunting that helps patients eat less may simultaneously suppress the biological hunger signals that normally correct for emerging nutrient gaps.

Body composition data revealed a second dimension of concern. Across drug classes, fat-free mass, the non-adipose component of body weight that includes muscle, bone, organs, and fluids, declined significantly. Tirzepatide 15 mg was associated with a mean fat-free mass reduction of 1.60 kg, representing 14.30 percent of total weight lost, while semaglutide 1.0 mg produced a 0.80 kg decline constituting 11.60 percent of weight reduction. The researchers emphasize that fat-free mass is not synonymous with skeletal muscle mass, and only one mechanism-of-action study reported appendicular lean mass as a muscle proxy. Even so, the proportional loss of lean tissue raises the prospect of sarcopenic obesity, a condition combining reduced muscle mass with metabolic dysfunction. The risk is sharpened by the finding that 7.26 percent of participants crossed a body mass index below 22 kg/m2, a threshold at which clinical protocols recommend modifying intake to prevent physical frailty.

The contrast between clinical reporting and laboratory reality forms the analytical centerpiece of the review. Pooled analysis of MedDRA-coded malnutrition events across the SURMOUNT 1-4 trials produced a non-significant risk ratio of 2.38, suggesting standard adverse event capture missed most nutritional deterioration. Total lymphocyte count below 910 per microliter, a marker independently associated with impaired immune function, delayed wound healing, and increased infection susceptibility, appeared in 2.90 percent of active therapy participants, nearly double the placebo rate, with a statistically significant risk ratio of 1.64. Meanwhile, 0.38 percent of tirzepatide-treated participants reached an underweight classification during treatment, and investigator-reported vitamin deficiencies involving vitamin D, B12, and folate occurred in 0.99 percent, though none of the original protocols screened for these systematically at predetermined intervals.

Secondary metabolic stressors add another layer of physiological complexity. Pooled SCALE data documented a mean 31 percent increase in pancreatic lipase and 7 percent increase in amylase following liraglutide treatment, elevations that appeared early, persisted during therapy, were dose-independent, and reversed upon drug cessation. Although 12 cases of acute pancreatitis were confirmed in liraglutide arms, a 0.4 percent incidence, the positive predictive value of enzyme elevations alone was below 1 percent, indicating these biomarkers more likely represent subclinical pancreatic stress than acute inflammation. Whether comparable enzyme dynamics occur with tirzepatide or injectable semaglutide remains unknown, because neither the SURMOUNT nor STEP programs included pancreatic enzyme monitoring. Persistent subclinical pancreatic stress could theoretically introduce a malabsorptive component, potentially compromising fat-soluble vitamin status even in patients with adequate intake.

Individual variability in baseline physiology may determine who is most vulnerable. Deep-phenotyping research describes a ‘Calories to Satiation’ trait ranging from 140 to 2166 kilocalories among adults with obesity, and high-potency incretins may amplify this gut-brain axis signal to its maximum effect. People who already reach satiation at low caloric intakes could ‘overshoot’ intended restriction, a concern compounded by sex differences, since women generally reach satiation at lower energy intakes than men. In trials with predominantly female enrollment, such as SURMOUNT-1 at 67 percent and STEP 1 at 74 percent female, the observed magnitude of lean mass loss may partly reflect this lower baseline caloric threshold. Bone health introduces a further unmeasured dimension: rapid weight loss removes the mechanical loading stimulus that sustains bone mineral density in obesity, and bariatric surgery studies document significant bone loss within 12 to 24 months. No included trial measured bone density, leaving the skeletal consequences of drug-induced weight loss entirely unquantified.

To translate these findings into clinical practice, the researchers propose a Tiered Stepped-Care Algorithm built on the 1200 kilocalorie daily deficit as the mechanistic anchor. Step one mandates baseline screening for albumin, total lymphocyte count, and vitamin D to identify pre-existing vulnerabilities. Step two requires periodic monitoring of the deficit threshold alongside body composition shifts to detect excessive lean mass attrition. Step three activates intensive intervention, with immediate referral for Medical Nutrition Therapy, when serum albumin falls below 3.3 g/dL or total lymphocyte count drops below 910 per microliter. The framework mirrors nutritional oversight long considered standard for bariatric surgery patients, a population whose weight loss trajectories are comparable in magnitude to those produced by maximum-dose tirzepatide, which achieved 22.5 percent total body weight loss over 72 weeks in SURMOUNT-1.

The authors acknowledge important limitations. The original Phase 3 programs were designed to demonstrate weight loss efficacy and cardiometabolic safety, not nutritional outcomes, so reliance on post-hoc analyses likely underestimates true malnutrition prevalence. The 12-week minimum duration criterion may have excluded shorter mechanistic studies, the predominantly East Asian population in SURPASS-AP-Combo, with lower baseline body mass indices, limits generalizability to Western cohorts, and publication bias could not be excluded from secondary endpoints. Quality assessment using the Cochrane Risk-of-Bias tool found low risk across all major domains for the included programs, and Egger regression detected no significant publication bias for the primary outcome. Future trials, the researchers argue, should incorporate pre-specified dual-energy X-ray absorptiometry monitoring, serum micronutrient panels, fecal elastase testing, head-to-head comparisons in adults aged 65 and older with sarcopenia and bone density as co-primary outcomes, and follow-up of at least two years. Sustained weight reduction remains a legitimate therapeutic goal, the analysis concludes, but the data suggest it should no longer be pursued without the nutritional surveillance needed to protect the physiological integrity of the millions of patients now taking these medications.

Subject of Research: Systematic review and meta-analysis of malnutrition risk, energy restriction, and lean mass loss in high-potency incretin therapy

Article Title: A Systematic Review and Meta‐Analysis of Malnutrition and Metabolic Failure in High‐Potency Incretin Therapy

Article References: Ampofo, E., Apprey, C., Amoako, M., & Turkson, F. D. (2026). A Systematic Review and Meta‐Analysis of Malnutrition and Metabolic Failure in High‐Potency Incretin Therapy. Obesity Science & Practice, 12(5), Article e70188. https://doi.org/10.1002/osp4.70188

Image Credits: AI Generated

DOI: 10.1002/osp4.70188

Keywords: incretin therapy, semaglutide, tirzepatide, liraglutide, malnutrition, fat-free mass, weight loss, obesity, GLP-1 receptor agonists, nutritional monitoring, sarcopenia, meta-analysis

The study drew on data from a six-year, school-based physical activity initiative conducted in south-eastern Norway. Of 351 children whose parents provided consent, 330 completed at least one valid maximal treadmill test, an unusually rigorous approach in pediatric research where field estimates of fitness are far more common than direct measurement. Because valid peak oxygen uptake data from 2016 were available from only three of the nine participating schools following a technical data loss, the researchers based their inferential analyses on measurements collected in 2015, 2017, 2018, 2019 and 2020, providing a longitudinal window that spans most of primary school.

At the heart of the research lies a methodological question that has divided pediatric exercise scientists for decades: how should oxygen uptake be expressed when comparing children of different sizes? Raw absolute values in liters per minute naturally favor older, heavier children. Dividing by total body mass is the most common correction, but it penalizes children with higher body fat, who contribute mass but little metabolic machinery for running. Allometric scaling, which uses exponentials of body mass, and scaling to fat-free mass, which isolates metabolically active tissue, offer alternatives. The HOPP team, led by Asgeir Mamen of Kristiania University College, together with Julianna Buer of the Norwegian School of Sport Sciences and Per Morten Fredriksen of the University of Inland Norway, designated fat-free-mass-scaled peak oxygen uptake as their prespecified primary outcome and tracked all four expressions simultaneously.

The statistical architecture reflected the complexity of the design. Linear mixed models included test year, school allocation group, sex, and the interaction between test year and group as fixed effects, with participant identity as a random intercept and test year as the repeated factor. The primary model incorporated 904 observations from 314 children, a sample that gives the analysis substantial power to detect developmental trends. School-level models were run as sensitivity analyses to probe whether results were being driven by the clustering of children within individual schools, a known hazard of school-based interventions.

The headline result was unambiguous in direction, if nuanced in interpretation. Fat-free-mass-scaled peak oxygen uptake was significantly associated with test year, allocation group, sex, and the test year by group interaction, with all p-values at or below 0.030. From fifth to sixth grade, the adjusted mean fell by 5.73 milliliters per kilogram of fat-free mass per minute in the intervention group and by 5.11 in the control group. Critically, the difference between those group-specific changes was just 0.62 milliliters, with a 95 percent confidence interval spanning from minus 4.25 to 3.00 and a p-value of 0.736. In other words, the school-based physical activity program appeared to make no measurable difference to the final-year decline.

That equivalence between intervention and control schools is perhaps the study’s most sobering finding. The HOPP project was designed as a pedagogical experiment in which schools adopted enhanced physical activity programming, and the reasonable hope was that extra activity would buffer children against fitness losses as they approach adolescence. Instead, the data suggest the late-primary-school decline was resistant to the intervention as delivered. Body-mass-relative and allometrically scaled oxygen uptake also fell significantly in both groups during the final year, while absolute peak oxygen uptake, unadjusted for growth, held roughly steady, hinting that increases in raw aerobic capacity were simply failing to keep pace with children’s rapid physical development.

Sex differences emerged across every expression of fitness, with boys showing higher adjusted values than girls. Yet the magnitude of that gap depended heavily on how the data were scaled. When oxygen uptake was normalized to fat-free mass, which strips away the influence of differences in body composition between the sexes, the sex difference was substantially attenuated. This observation reinforces a growing consensus in pediatric physiology: apparent fitness gaps between boys and girls are partly artifacts of scaling choices and body composition rather than true differences in the oxidative capacity of muscle tissue.

The school-level sensitivity analyses added another layer of nuance. Changes in the three body-size-adjusted expressions of fitness were negative at all nine schools, suggesting the final-year decline was a pervasive phenomenon rather than a quirk of any particular classroom, neighborhood or teaching staff. Such consistency strengthens the biological plausibility of the trend, while also underscoring that whatever combination of growth, maturation and behavior drives the decline, it operates broadly across the study population and overwhelms school-level variation in programming.

The authors are candid about the limitations that temper firm causal conclusions. The study design could not separate growth-related developmental changes from shifts in behavior associated with the COVID-19 pandemic, which overlapped with the later measurement years and is known to have disrupted children’s physical activity worldwide, nor from the possibility that the composition of participants changed over time. A retrospective trial registration, dated 20 June 2015 on ClinicalTrials.gov as NCT02495714, and the 2016 data gap further complicate the inferential picture. Still, the convergence of negative findings across multiple scaling methods and all nine schools makes the late-primary decline difficult to dismiss as statistical noise.

For researchers, the message is methodological: conclusions about childhood aerobic fitness hinge materially on scaling method, body composition and school-level heterogeneity, and studies that report only a single expression of peak oxygen uptake may tell an incomplete or even misleading story. For parents, educators and policymakers, the findings add to mounting evidence that the transition out of primary school is a vulnerable window for children’s cardiovascular health, one that conventional school-based activity interventions, at least as implemented in HOPP, did not shield against. Identifying what does work during those years, and distinguishing genuine developmental biology from modifiable behavior, now stands as an urgent task for pediatric exercise science.

Subject of Research: Longitudinal development of peak oxygen uptake in 6- to 12-year-old children

Article Title: Longitudinal development of oxygen uptake in 6- to 12-year-old children: the Health Oriented Pedagogical Project (HOPP)

Article References: Mamen, A., Buer, J., & Fredriksen, P. M. (2026). Longitudinal development of oxygen uptake in 6- to 12-year-old children: the Health Oriented Pedagogical Project (HOPP). BMC Pediatrics. https://doi.org/10.1186/s12887-026-07631-7

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07631-7

Keywords: peak oxygen uptake, aerobic fitness, children, fat-free mass, allometric scaling, treadmill running, primary school, physical activity, longitudinal study, pediatric health, HOPP, Norway